Sign in

    Rye Forseth

    Research Analyst at Guggenheim Securities

    Rye Forseth is an analyst at Guggenheim Securities, focusing on biotechnology equity research with company coverage that includes Soleno Therapeutics and Voyager Therapeutics among others. His performance record includes active participation in earnings calls and is documented through Fintool, with at least seven company interactions tracked, though published reporting metrics such as TipRanks rankings or quantified success rates are not publicly available. Forseth has been with Guggenheim Securities through several recent earnings cycles, with no widely reported prior firm experience or notable industry awards cited in current public records. His professional credentials and securities licenses are not disclosed in available sources.

    Rye Forseth's questions to SOLENO THERAPEUTICS (SLNO) leadership

    Rye Forseth's questions to SOLENO THERAPEUTICS (SLNO) leadership • Q2 2025

    Question

    Rye Forseth asked about any emerging challenges or 'pain points' in the patient start form process that could be addressed in the coming quarters. He also inquired about how early patient compliance trends are tracking since the launch.

    Answer

    CEO Anish Bhatnagar explained that with a very strong start of 646 patient forms, it is difficult to predict specific pain points for this first-ever hyperphagia drug launch, but the company is monitoring variables like seasonality. Regarding compliance, he stated that while it is too early for detailed data, observed discontinuation rates are substantially lower than those seen in clinical trials, which already had high compliance.

    Ask Fintool Equity Research AI

    Rye Forseth's questions to SOLENO THERAPEUTICS (SLNO) leadership • Q2 2025

    Question

    Rye Forseth from Guggenheim Securities asked about any emerging challenges or 'pain points' in the patient start form process. He also inquired about early patient compliance and discontinuation trends for VICAT XR.

    Answer

    CEO Anish Bhatnagar stated that with 646 start forms, the launch has been very strong and it's too early to predict specific pain points, though they are monitoring factors like seasonality. Regarding compliance, he noted that while it's early, discontinuation rates are substantially lower than what was observed in clinical trials.

    Ask Fintool Equity Research AI